The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. While Soliris had its market launch 17 years ago with $3.2 billion in sales in 2023, Ultomiris was approved in 2018 and generated $3 billion in revenue last year.

FDA Approval 102

FDA Approval Sales Trials Development 102

XTalks

JANUARY 4, 2024

Hemophilia B, also known as congenital Factor IX (FIX) deficiency or Christmas disease, is a rare genetic bleeding disorder caused by a deficiency or defect in the FIX clotting protein. Treatment involves replacing the missing FIX clotting protein, traditionally through regular infusions. Priced at $3.5

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

Delveinsight

JANUARY 12, 2021

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant. Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. AvantGen Enters into a Licensing Agreement for its Anti-SARS-CoV-2 Antibodies with IGM Biosciences.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Roots Analysis

FEBRUARY 26, 2024

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

pharmaphorum

DECEMBER 2, 2021

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. billion if the drug reaches the market and hits sales objectives.

Antibody 110

Antibody Licensing Licensing Gene Therapy 110

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The post Sanofi places $75m bet with ABL on popular Parkinson’s drug target appeared first on.

Antibody 97

Antibody Drugs Protein Licensing 97

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) hold the number 2 and number 11 spots, respectively, in annual sales of the top oncology products. Herceptin (Trastuzumab) and Mabthera (Rituximab).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

pharmaphorum

APRIL 19, 2022

[So] we are trying to go for the international market.”. “In Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025. David Julius, who discovered TRPV1 in 1997, was recognized with Nobel Prize in Medicine last year for his work with TRP proteins).

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 million and US$1.8 About Juyou Bio – Technology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. It has licensed in a patented breathalyser, the analysts noted. A femtogram is 0.000000000000000001 kilograms.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 67

Antibody Licensing Licensing Sales 67

pharmaphorum

MARCH 31, 2021

Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . Novartis licenses the drug from Genmab and reformulated into its Sensoready autoinjector pen. billion or more in peak sales.

Licensing 98

Licensing Licensing Sales Gene Therapy 98

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. Dragonfly received U.S.

Licensing 52

Licensing Licensing Development Production 52

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373. The candidate is built upon a stable, prefusion protein and includes Novavax’s Matrix?M M adjuvant.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The most common heteroatoms are nitrogen (N), oxygen (O) and sulphur (S). Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

JUNE 20, 2022

The deal gives Valneva a cash injection that it will be able to use to advance Lyme disease candidate VLA15 towards the market, but the revised licensing terms means that the French biotech will shoulder more of the financial cost of the development programme.

Vaccination 98

Vaccination Vaccine Licensing Licensing 98

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies. The firm predicts sales of KarXT could reach $2.8

Drugs 52

Drugs FDA Approval Sales Vaccination 52

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. Under the agreement, Boehringer Ingelheim has the option to license dark antigens discovered and validated by Enara Bio.

Genome 66

Genome Genomics Licensing Licensing 66

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

Drug Discovery World

AUGUST 31, 2022

Moderna also alleges Pfizer and BioNTech copied Moderna’s approach to encode for the full-length spike protein in a lipid nanoparticle formulation for a coronavirus. ” Moderna is not looking to remove Comirnaty from the market or to prevent future sales. Something it alleges Pfizer and BioNTech have failed to do.

Vaccination 52

Vaccination Vaccine Sales RNA 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. billion in pharmaceutical sales from 2021. billion, a 42.74

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. The drug made $445 million in sales last year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). GPCR – G protein-coupled receptors. . TOKYO and CAMBRIDGE, England , Dec.

Licensing 40

Licensing Licensing Production Development 40

pharmaphorum

OCTOBER 29, 2020

The Swiss pharma group already sells one gene therapy for inherited retinal diseases (IRDs) – Luxturna (voretigene neparvovec) – for which it licensed ex-US rights from Spark Therapeutics (now part of Roche) in 2018. Novartis’ big move in the gene therapy market came when it bought AveXis for $8.7

Gene Therapy 40

Gene Therapy Gene Gene Silencing Protein 40

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . When errors in the process occur it can lead to mutations that cause cancer, as well as many other diseases.

RNA 52

RNA Licensing Licensing Development 52

pharmaphorum

NOVEMBER 23, 2021

GSK gets worldwide rights to the potentially first-in-class drug, with the exception of China, and will be wholly responsible in its markets for clinical development and commercialisation. Preliminary data has shown that the drug can reduce levels of HSD17B13 protein as well as other liver enzymes that are biomarkers for NASH.

Sales 52

Sales Drugs Trials RNA 52

pharmaphorum

JANUARY 31, 2022

It’s a setback to Pfizer’s late-stage pipeline, given that at one point the company was projecting $3 billion in potential sales for vupanorsen, which targets ANGPTL3 protein and is playing catch-up in the category with Regeneron’s already-marketed Evkeeza (evinacumab).

Production 52

Production Vaccination Vaccine Trials 52

pharmaphorum

SEPTEMBER 18, 2020

German and Swiss pharma companies dominated the Swedish market at this time and it wasn’t until 1913 that the discussions were turned into a pharmaceutical company, Astra AB. Astra introduced two important product families onto the Swedish market in 1948: penicillin and anaesthetics, initially in the form of Xylocaine.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

XTalks

DECEMBER 13, 2023

In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. Xoma’s unique approach involves acquiring future economic interests tied to pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

OCTOBER 27, 2021

Lilly has also picked up an accelerated review for donanemab from the FDA, which is assessing the drug under a rolling license application that will see data submitted to the agency as it becomes available. Cortexyme trial disappoints.

Trials 52

Trials Drugs Sales Bacteria 52

pharmaphorum

JANUARY 18, 2021

J&J’s Janssen pharma unit got approval for Darzalex Faspro as a multiple myeloma treatment in the US last May and in Europe the following month, lending further momentum to a franchise that looks set to make more than $4 billion in sales in calendar 2020.

Drugs 98

Drugs Licensing Licensing Production 98

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. The startup recently raised USD 87 million to propel itself in a competitive market. Ikena will back a pipeline that falls into two categories.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

XTalks

JUNE 12, 2023

Medtronic’s Hugo Robotic-Assisted Surgery system , released in a limited market in June 2021, has been receiving positive reviews for its performance in various surgeries. Medtronic is optimistic about this opportunity and anticipates high demand across a large global market. billion in 2022, an increase of 1.36 percent from $27.06

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

pharmaphorum

AUGUST 7, 2020

Roche’s drug is already licensed in more than 70 countries as a front-line treatment for PD-L1-positive forms of TNBC in a regimen with Bristol-Myers Squibb’s Abraxane (nab-paclitaxel) – a form of paclitaxel bound to the blood protein albumin to improve its delivery side effects – based on the IMpassion130 trial.

Trials 52

Trials Drugs Licensing Licensing 52

pharmaphorum

AUGUST 16, 2020

ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and should be ready for first deliveries before the end of the year. It will be provided on a no-profit basis while the pandemic is ongoing.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52